A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer

NCT00697060 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study cancelled prior to start due to change in company priorities.

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Imexon + docetaxel

Sponsor

AmpliMed Corporation